Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2019
2019
Project start date :
07 / 01 / 2019
07 / 01 / 2019
Project end date :
03 / 30 / 2022
03 / 30 / 2022
Project duration (months) :
24 / 22
24 / 22
Development stage :
Preclinical
Preclinical
Target disease :
DTwP-HepB-IPV-Hib (Hexavalent vaccine)
DTwP-HepB-IPV-Hib (Hexavalent vaccine)
Region served :
Low- and Middle-Income Countries
Low- and Middle-Income Countries
Recipient organization / Country of funding recipient organization :
LG Chem / Republic of Korea
LG Chem / Republic of Korea
Collaborator(s) / Country :
-
-
Funding amount(KRW) :
4,000,000,000
4,000,000,000
This project focuses on the process development of a DTwP-HepB-Hib-IPV hexavalent vaccine formulation. LG Chem has already successfully completed the scale-up of a 10-dose vial formulation to commercial-scale production (800 kg). The validated process will be used for the production of drug products for further clinical evaluation. The hexavalent vaccine fills an important gap in the coverage of inactivated poliovirus vaccine (IPV) due to global shortages, and will help to simplify complex pediatric immunization schedules.